Acabrunat (Acalabrutinib) 100 mg
Acabrunat is a next-generation targeted therapy for blood cancers. Active ingredient: Acalabrutinib (100 mg).
Manufacturer: Natco Pharma (India). Generic equivalent of Calquence.
The "Safer" BTK Inhibitor:
Acabrunat is a highly selective Bruton tyrosine kinase (BTK) inhibitor. Unlike the first-generation drug (Ibrutinib), it has less "off-target" activity. This means a significantly lower risk of cardiac arrhythmias (atrial fibrillation) and severe bleeding, making it a safer choice for elderly patients.
✅ Advantage: Powerful efficacy with fewer side effects.
Indicated for the treatment of adult patients with:
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Both treatment-naive and relapsed/refractory cases.
- Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.
Standard Dosage: 100 mg capsule taken orally twice daily (approximately every 12 hours).
⚠️ CRITICAL INTERACTION WARNING (Stomach Acid):
Acalabrutinib requires stomach acid for absorption.
- 🚫 AVOID PPIs: Do not take Proton Pump Inhibitors (e.g., Omeprazole, Esomeprazole, Pantoprazole). They drastically reduce the drug's effectiveness.
- ✅ H2 Blockers/Antacids: Take Acabrunat 2 hours before taking antacids (like Calcium Carbonate) or H2-blockers (like Famotidine).
- Active serious bleeding.
- Upcoming surgery (Stop therapy 3–7 days pre- and post-surgery).
- Severe hepatic impairment.
- Pregnancy and breastfeeding.
- Concomitant use of Warfarin (increases bleeding risk).
Generally well-tolerated. Common adverse reactions include:
- Headache: Very common initially. Usually manageable with caffeine or mild analgesics and resolves over time.
- Diarrhea.
- Bruising: Increased tendency to bruise.
- Neutropenia (low white blood cell count).
Similar products
What Customers Say
No reviews yet
Your review can be the first!